Key Points
- Major shareholder Chidozie Ugwumba has been selling large blocks of CLNN throughout December — including a 56,577-share sale on Dec. 3 and a Dec. 30 sale of 4,138 shares at $6.03 ($24,952.14) — and now directly owns 783,590 shares, with the transactions disclosed in an SEC filing.
- Clene reported a notable quarterly EPS miss on Nov. 13 (‑$0.85 vs. ‑$0.60 expected) with minimal revenue, underlining ongoing cash burn and clinical-stage risk that could amplify downside from insider sales.
- The stock has a market cap of about $60.6M and a 1‑year range of $2.28–$13.50, while analysts hold a consensus "Moderate Buy" with an average price target of $32.60, indicating bullish expectations despite current weakness.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 4,138 shares of the stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $6.03, for a total transaction of $24,952.14. Following the sale, the insider directly owned 783,590 shares of the company's stock, valued at approximately $4,725,047.70. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total transaction of $48,171.20.
- On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $42,830.37.
- On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The shares were sold at an average price of $6.32, for a total value of $21,172.00.
- On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $9,342.30.
- On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total transaction of $28,560.18.
- On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The shares were sold at an average price of $6.45, for a total value of $36,003.90.
- On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The shares were sold at an average price of $7.86, for a total transaction of $444,695.22.
- On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The stock was sold at an average price of $6.33, for a total value of $36,815.28.
- On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The shares were sold at an average price of $6.61, for a total value of $19,063.24.
- On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The stock was sold at an average price of $6.31, for a total transaction of $44,359.30.
Clene Trading Down 1.5%
Shares of CLNN opened at $5.87 on Thursday. The stock has a 50 day simple moving average of $8.16 and a 200-day simple moving average of $6.34. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The stock has a market cap of $60.64 million, a PE ratio of -1.73 and a beta of 0.79.
Clene (NASDAQ:CLNN - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, sell-side analysts forecast that Clene Inc. will post -5.19 EPS for the current fiscal year.
Institutional Investors Weigh In On Clene
Institutional investors have recently made changes to their positions in the company. Lunt Capital Management Inc. increased its position in Clene by 71.2% during the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company's stock worth $199,000 after buying an additional 21,217 shares during the period. Jane Street Group LLC acquired a new position in shares of Clene during the 2nd quarter worth $47,000. Scoggin Management LP lifted its holdings in shares of Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company's stock worth $558,000 after acquiring an additional 42,750 shares during the last quarter. Finally, Jones Financial Companies Lllp acquired a new stake in Clene in the third quarter valued at approximately $29,000. Institutional investors own 23.28% of the company's stock.
Key Clene News
Here are the key news stories impacting Clene this week:
- Positive Sentiment: Several brokers maintain Buy ratings and a high consensus price target (MarketBeat shows a consensus target well above current levels), which can provide upside if clinical progress improves. Analyst Coverage and Price Targets
- Neutral Sentiment: Small institutional investors have been adding positions in recent quarters (e.g., Jane Street, Lunt Capital, Scoggin Management), and roughly 23% of shares are held by hedge funds/institutions — a neutral signal that can stabilize trading but is not large enough to offset heavy insider sales alone. Institutional Ownership Details
- Negative Sentiment: Major shareholder Chidozie Ugwumba has been selling repeatedly through December — multiple transactions (including a 56,577-share sale on Dec. 3 and several multi-thousand-share blocks later in the month). These disclosed SEC sales increase supply and likely pressure the stock. See SEC filing for the December transactions. Insider Sale SEC Filing
- Negative Sentiment: Fundamental headwinds remain: the company reported a significant quarterly EPS miss (Nov. 13) with minimal revenue, underscoring ongoing cash-burn and clinical-stage risk — factors that amplify negative reaction to insider sales. Earnings and Financials
Wall Street Analyst Weigh In
A number of research analysts have commented on CLNN shares. D. Boral Capital reiterated a "buy" rating and issued a $23.00 price objective on shares of Clene in a research report on Wednesday, December 10th. Benchmark reissued a "buy" rating on shares of Clene in a report on Thursday, December 4th. UBS Group reaffirmed a "buy" rating on shares of Clene in a research note on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Clene in a report on Tuesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $32.60.
Check Out Our Latest Analysis on CLNN
About Clene
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
